Zobrazeno 1 - 10
of 53
pro vyhledávání: '"Filippo de Marinis"'
Autor:
Federico Cucchiara, Iacopo Petrini, Antonio Passaro, Ilaria Attili, Stefania Crucitta, Eleonora Pardini, Filippo de Marinis, Romano Danesi, Marzia Del Re
Publikováno v:
Clinical Lung Cancer. 23:510-521
Small cell lung cancer (SCLC) is an aggressive tumor, and despite its sensitivity to chemotherapy and radiotherapy, patients usually have a short survival. There are no clinically relevant predictive factors of responses to therapies, and therapeutic
Autor:
Filippo Lococo, Alessandra Cancellieri, Marco Chiappetta, Alessandro Leonetti, Giuseppe Cardillo, Francesca Zanelli, Giuseppe Mangiameli, Luca Toschi, Gianluca Guggino, Francesco Jacopo Romano, Giovanni Leuzzi, Claudia Proto, Lorenzo Spaggiari, Filippo De Marinis, Emanuele Vita, Luca Ampollini, Stefano Margaritora, Marcello Tiseo, Emilio Bria
Publikováno v:
Clinical Lung Cancer.
Autor:
Giulia Corrao, Matteo Franchi, Mattia Zaffaroni, Maria Giulia Vincini, Filippo de Marinis, Lorenzo Spaggiari, Roberto Orecchia, Giulia Marvaso, Barbara Alicja Jereczek-Fossa
Publikováno v:
Cancers
Volume 15
Issue 4
Pages: 1103
Volume 15
Issue 4
Pages: 1103
Aim: Healthcare administrative databases represent a valuable source for real-life data analysis. The primary aim of this study is to compare effectiveness and cost profile in non-small-cell lung cancer (NSCLC) patients harboring synchronous brain me
Autor:
Shehab Mohamed, Luca Bertolaccini, Domenico Galetta, Francesco Petrella, Monica Casiraghi, Filippo de Marinis, Lorenzo Spaggiari
Publikováno v:
Cancers. 15:2476
Many new treatment modalities for non-small-cell carcinoma (NSCLC) have been described in the last two decades. Surgical resections remain the gold standard for early stages and may be considered for locally advanced tumors. Medical treatment has cha
Autor:
Paolo Tarantino, Ilaria Attili, Filippo de Marinis, Giuseppe Curigliano, Valeria Stati, Antonio Passaro
Publikováno v:
Lung Cancer. 154:151-160
The adoption of Immune checkpoint inhibitors (ICIs) allowed the achievement of impressive long-term survival results in non-small cell lung cancer (NSCLC), but most patients develop resistance to ICI treatment over time. Resistance to ICIs is mediate
Rescue Surgery after Immunotherapy/Tyrosine Kinase Inhibitors for Initially Unresectable Lung Cancer
Publikováno v:
Cancers; Volume 14; Issue 11; Pages: 2661
Background: We report the outcomes for unresectable patients with locally advanced or oligometastatic non-small cell lung cancer (NSCLC) treated with tyrosine kinase inhibitor (TKI) or immunotherapy who achieved a clinical downstaging so as to re-ent
Autor:
Lorenzo Spaggiari, Marina Chiara Garassino, Filippo de Marinis, Roberto Ferrara, Giulia Marvaso, Barbara Alicja Jereczek-Fossa, Gaia Piperno, Giuseppe Lo Russo, Giulia Corrao, Roberto Orecchia, Simone Giovanni Gugliandolo
Publikováno v:
Lung Cancer. 142:70-79
Presence of liver metastases correlates with worse survival and response to any treatments. This may be due to the microenvironment of liver which leads tumor to escape from Immune System. Stereotactic Body Radiation Therapy may help to sensitize Imm
Autor:
Paolo Bidoli, Daniele Turci, Hector Soto Parra, Domenico Galetta, Fabiana Vitiello, Teresa Gamucci, Paola Antonelli, Filippo de Marinis, Giuseppe Lo Russo, Angelo Delmonte, Enrico Cortesi, Francesco Grossi, Luana Calabrò, Andrea Ardizzoni, Alessandro Morabito, Diana Giannarelli, Antonio Chella, Federico Cappuzzo, Lucio Crinò, Marcello Tiseo
Publikováno v:
The Oncologist. 24:e1165-e1171
Background Nivolumab has shown a survival benefit compared with docetaxel as second-line treatment for patients with previously treated advanced squamous non-small cell lung cancer (NSCLC) in a randomized phase III trial. The experiences of patients
Autor:
Carlo Putzu, Filippo de Marinis, Laura Bonanno, Sara Pilotto, Antonio Passaro, Lorenza Landi, Carlo Genova, Danilo Rocco, Rita Chiari, Luca Toschi, Chiara Bennati, Arsela Prelaj, Diego Cortinovis, Andrea Camerini, Marcello Tiseo, Claudia Proto, Federico Cappuzzo, Claudio Sini, Alessandro Tuzi, Giulio Cerea, Gianluca Spitaleri
Publikováno v:
Clinical Lung Cancer. 20:e186-e194
Background Molecular characterization of non–small-cell lung cancer (NSCLC), defined predictive and druggable mutations that greatly modified patient prognoses. The most frequent driver mutations detected in NSCLC are epidermal growth factor recept
Autor:
J. Goldschmidt, Keunchil Park, Filippo de Marinis, M. Gandhi, Paul Conkling, Achim Rittmeyer, Rimas V. Lukas, Joachim von Pawel, Shirish M. Gadgeel, Carol O'Hear, Marcus Ballinger, Alan Sandler, Diego Cortinovis, Sylvia Hu, Catherine Lai, Lou Fehrenbacher, Jyoti D. Patel
Publikováno v:
Lung Cancer. 128:105-112
Objectives To assess the safety and efficacy of atezolizumab and docetaxel in patients with and without a history of asymptomatic, treated brain metastases in the phase III OAK trial. Materials and methods Patients received 1200 mg atezolizumab or 75